Expand / Albert Bourla, chief executive officer of Pfizer pharmaceutical firm, bangs a gavel after ringing the closing bell at the New York Stock Exchange (NYSE) on Thursday afternoon, January 17, 2019 at nyc. (charge: Getty | Drew Angerer)
Pfizer’s chief executive has conducted some lingering hope that we will peek COVID-19 vaccine information before the next week’s election.
The pharmaceutical giant has got the speediest clinical-trial style one of the frontrunners at the COVID-19 embryo race. And for months, Pfizer CEO Albert Bourla has the risk that his firm would have consequences at the end of October–an alluring prospect picked up from President Donald Trump, that has driven October vaccine information to strengthen his re-election bidding .
However, in a telephone with shareholders Tuesday, Bourla signaled an October launch was almost impossible today. Researchers conducting the above 40,000-person trial haven’t yet examined preliminary information along with data, even if the information were available elsewhere, an external panel would require no less than a week to test any outcomes, Bourla explained.
Read 5 staying sentences | Remarks
